Literature DB >> 22495743

A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo.

Aws Abdul-Wahid1, Eric H-B Huang, Huixin Lu, Jean Flanagan, Amirul Islam Mallick, Jean Gariépy.   

Abstract

Metastatic forms of cancers remain the main cause of death in cancer patients. In this study, we demonstrate that directing a sustained antibody response towards the homotypic binding function of CEA interferes with the implantation and development of tumor foci in CEA-expressing transgenic (CEA.Tg) mice. Specifically, vaccinating CEA.Tg mice with a recombinant, altered self-form of the CEA Ig V-like N domain led to the production of circulating IgG1 and IgG2a antibodies that inhibited CEA-mediated adhesion of murine carcinoma expressing CEA (MC38.CEA) and mediated antibody-dependent lysis of tumor cells. Moreover, vaccinated CEA.Tg mice were resistant to the development of tumor nodules in the lungs and the peritoneal cavity, suggesting that mounting a focused antibody response to the CEA N domain may represent a simple therapeutic strategy to control the establishment of metastatic foci in cancer patients.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495743     DOI: 10.1002/ijc.27582

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen.

Authors:  Erik W Orava; Aws Abdul-Wahid; Eric H-B Huang; Amirul Islam Mallick; Jean Gariépy
Journal:  Mol Oncol       Date:  2013-04-11       Impact factor: 6.603

2.  The carcinoembryonic antigen IgV-like N domain plays a critical role in the implantation of metastatic tumor cells.

Authors:  Aws Abdul-Wahid; Eric H-B Huang; Marzena Cydzik; Eleonora Bolewska-Pedyczak; Jean Gariépy
Journal:  Mol Oncol       Date:  2013-12-17       Impact factor: 6.603

3.  Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Authors:  Marijo Bilusic; Christopher R Heery; Philip M Arlen; Myrna Rauckhorst; David Apelian; Kwong Y Tsang; Jo A Tucker; Caroline Jochems; Jeffrey Schlom; James L Gulley; Ravi A Madan
Journal:  Cancer Immunol Immunother       Date:  2013-12-07       Impact factor: 6.968

4.  Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.

Authors:  Aws Abdul-Wahid; Marzena Cydzik; Nicholas W Fischer; Aaron Prodeus; John E Shively; Anne Martel; Samira Alminawi; Zeina Ghorab; Neil L Berinstein; Jean Gariépy
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

5.  Reduced DAXX Expression Is Associated with Reduced CD24 Expression in Colorectal Cancer.

Authors:  Ya-Chun Chen; Tsung-Hsien Lee; Shu-Ling Tzeng
Journal:  Cells       Date:  2019-10-12       Impact factor: 6.600

6.  Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers.

Authors:  Aaron Prodeus; Aws Abdul-Wahid; Nicholas W Fischer; Eric H-B Huang; Marzena Cydzik; Jean Gariépy
Journal:  Mol Ther Nucleic Acids       Date:  2015-04-28       Impact factor: 10.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.